| 1 |
金雪娟, 周京敏. 心力衰竭与心房颤动共存的流行病学和相关临床研究进展 [J]. 临床心血管病杂志, 2019, 35(3): 199-202.
|
| 2 |
Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the framingham heart study: a cohort study [J]. Lancet, 2015, 386(9989): 154-162.
|
| 3 |
Chiang CE, Naditch-Brûlé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry [J]. Circ Arrhythm Electrophysiol, 2012, 5(4): 632-639.
|
| 4 |
Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the framingham heart study [J]. Circulation, 2003, 107(23): 2920-2925.
|
| 5 |
Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry [J]. Eur J Heart Fail, 2017, 19(12): 1574-1585.
|
| 6 |
Schotten U, Dobrev D, Platonov PG, et al. Current controversies in determining the main mechanisms of atrial fibrillation [J]. J Intern Med, 2016, 279(5): 428-438.
|
| 7 |
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur Heart J, 2021: 42(36): 3599-3726.
|
| 8 |
Chourdakis E, Koniari I, Velissaris D, et al. Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives [J]. J Geriatr Cardiol, 2021, 18(5): 362-375.
|
| 9 |
Kotecha D, Chudasama R, Lane DA, et al. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death and adverse outcomes [J]. Int J Cardiol, 2016, 203: 660-666.
|
| 10 |
Heart Failure Group of Chinese Society of Cardiology of Chinese Medical Association; Chinese Heart Failure Association of Chinese Medical Doctor Association; Editorial Board of Chinese Journal of Cardiology. [Chinese guidelines for the diagnosis and treatment of heart failure 2018] [J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2018, 46(10): 760-789.
|
| 11 |
毛文娟. β受体阻滞剂治疗心力衰竭合并房颤患者的疗效及安全性 [J]. 实用临床医药杂志, 2019, 23(2): 33-36.
|
| 12 |
杨颖. 探讨β受体阻滞剂治疗心力衰竭合并房颤患者的疗效及安全性 [J/OL]. 中西医结合心血管病电子杂志, 2020, 8(15): 47.
|
| 13 |
曾铖. β受体阻断药在心力衰竭合并房颤治疗中的效果 [J/OL]. 中西医结合心血管病电子杂志, 2016, 4(15): 73-74.
|
| 14 |
Cadrin-Tourigny J, Shohoudi A, Roy D, et al. Decreased mortality with beta-blockers in patients with heart failure and coexisting atrial fibrillation: An AF-CHF substudy [J]. JACC Heart Fail, 2017, 5(2): 99-106.
|
| 15 |
Komajda M, Böhm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis [J]. Eur J Heart Fail, 2018, 20(9): 1315-1322.
|
| 16 |
Joseph P, Swedberg K, Leong DP, et al. The evolution of beta-blockers in coronary artery disease and heart failure (Part 1/5) [J]. J Am Coll Cardiol, 2019, 74(5): 672-682.
|
| 17 |
Fiuzat M, Wojdyla D, Kitzman D, et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial [J]. J Am Coll Cardiol, 2012, 60(3): 208-215.
|
| 18 |
Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials [J]. Eur Heart J, 2018, 39(1): 26-35.
|
| 19 |
Ahn MS, Yoo BS, Son JW, et al. Beta-blocker Therapy at discharge in patients with acute heart failure and atrial fibrillation [J]. J Korean Med Sci, 2020, 35(33): e278.
|
| 20 |
顾盼盼, 吴继雄. β受体阻滞剂治疗心衰合并房颤患者的疗效观察 [C]. 湖南中医药大学学报2016/专集: 国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会论文集2016: 116-117.
|
| 21 |
黄华珊. β受体阻滞剂治疗心力衰竭合并房颤患者的疗效及安全性的META分析 [D]. 济南: 山东大学, 2017.
|
| 22 |
Karwath A, Bunting KV, Gill SK, et al. Redefining β-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: a machine learning cluster analysis [J]. Lancet, 2021, 398(10309): 1427-1435.
|
| 23 |
Kotecha D, Holmes J, Krum H, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis [J]. Lancet, 2014, 384(9961): 2235-2243.
|
| 24 |
Mareev Y, Cleland JG. Should beta-blockers be used in patients with heart failure and atrial fibrillation? [J]. Clin Ther, 2015, 37(10): 2215-2224.
|
| 25 |
Thackray SD, Ghosh JM, Wright GA, et al. The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers [J]. Am Heart J, 2006, 152(4): 713 e9-13.
|
| 26 |
Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin--analysis from the AFFIRM study [J]. Eur Heart J, 2013, 34(20): 1481-1488.
|
| 27 |
Li SJ, Sartipy U, Lund LH, et al. Prognostic significance of resting heart rate and use of beta-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish heart failure registry [J]. Circ Heart Fail, 2015, 8(5): 871-879.
|
| 28 |
王传合, 孙志军, 李晓东. 心力衰竭合并心房颤动的治疗策略选择 [J]. 中国实用内科杂志, 2020, 40(12): 996-1000.
|
| 29 |
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [J]. J Am Coll Cardiol, 2014, 64(21): e1-76.
|
| 30 |
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS [J]. Eur Heart J, 2016, 37(38): 2893-2962.
|
| 31 |
Van Gelder IC, Groenveld HF, Crijns HJ,et al. Lenient versus strict rate control in patients with atrial fibrillation [J]. N Engl J Med, 2010, 15, 362(15): 1363-1373.
|
| 32 |
Bisson A, Ding WY, Bodin A, et al. Clinical outcomes with digoxin vs. beta-blocker for heart rate control in permanent atrial fibrillation with heart failure [J]. Eur J Heart Fail, 2021, 23(9): 1563-1565.
|
| 33 |
Pellicori P, Zhang J, Lukaschuk E, et al. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value [J]. Eur Heart J, 2015, 36(12): 733-742.
|
| 34 |
Kawabata M, Hirao K, Hachiya H, et al. Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure [J]. J Cardiol, 2011, 58(2): 108-115.
|
| 35 |
Roy D, Talajic M, Nattel S,et al. Rhythm control versus rate control for atrial fibrillation and heart failure [J]. N Engl J Med, 2008, 358(25): 2667-2677.
|
| 36 |
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure [J]. N Engl J Med, 1997, 336(8): 525-533.
|
| 37 |
Marrouche NF, Kheirkhahan M, Brachmann J, et al. Catheter ablation for atrial fibrillation with heart failure [J]. N Engl J Med, 2018, 378(5): 417-427.
|